Catheter

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023
DNA, Conditional sentence, Patient, Segment, Prostate, Therapy, Diagnosis, Growth, Neurology, Hospital, Stroke, DNA synthesis, ChromeOS, Telehealth, Massive parallel sequencing, Ambulatory Surgery Center Association, Food, Prevalence, Cardinal Health, Catheter, Catalent, Suture, Drug development, NGS, Synthetic biology, SPECT, Syringe, Market, Bandage, Cardiology, Research, Biotechnology, Health information management, FDG, PET, Stent, Classification, EHR, De novo, Distribution, Countertop, Cardiovascular disease, TURP, Medication, COVID-19, Death, Splenic infarction, Oncology, Beauty salon, Health insurance, Medical imaging, Pharmaceutical industry, Medical device, Geography, Endocrinology, Application, Vygon (UK)

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

IV Catheters Market to Reach $17.8 Billion, Globally, by 2032 at 7.5% CAGR: Allied Market Research

Retrieved on: 
Thursday, November 16, 2023
Well, Risk, Infection, Growth, Hospital, Genomics, Safety, Patient, Research, Conditional sentence, Catheter, Prevalence, Health, Medical device

This could affect patients' ability to access and afford IV catheters products, potentially leading to decreased demand for these products.

Key Points: 
  • This could affect patients' ability to access and afford IV catheters products, potentially leading to decreased demand for these products.
  • This may result in a decrease in the volume of medical procedures and treatments, including those that require IV catheters.
  • By type, the peripheral IV catheters segment held the largest market share in 2022, accounting for around three-fifths of the global IV catheters market and is estimated to maintain its dominance during the forecast period.
  • Well-developed healthcare infrastructure and rise in prevalence of chronic diseases promoted the growth of the IV catheters market in North America.

IV Catheters Market to Reach $17.8 Billion, Globally, by 2032 at 7.5% CAGR: Allied Market Research

Retrieved on: 
Thursday, November 16, 2023
Well, Risk, Infection, Growth, Hospital, Genomics, Safety, Patient, Research, Conditional sentence, Catheter, Prevalence, Health, Medical device

This could affect patients' ability to access and afford IV catheters products, potentially leading to decreased demand for these products.

Key Points: 
  • This could affect patients' ability to access and afford IV catheters products, potentially leading to decreased demand for these products.
  • This may result in a decrease in the volume of medical procedures and treatments, including those that require IV catheters.
  • By type, the peripheral IV catheters segment held the largest market share in 2022, accounting for around three-fifths of the global IV catheters market and is estimated to maintain its dominance during the forecast period.
  • Well-developed healthcare infrastructure and rise in prevalence of chronic diseases promoted the growth of the IV catheters market in North America.

Global Market for Medical Devices, 13th Edition: A Comprehensive Analysis of the Medtech Sector's Current Scope and Emerging Trends - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Medical Devices, Health, Ageing, Catheter, Medtech, Organization, Medical device, Research, Metabolism, Patient, Diagnosis, Longevity

The medical device industry, commonly referred to as the medtech industry, plays a pivotal role within the broader healthcare sector.

Key Points: 
  • The medical device industry, commonly referred to as the medtech industry, plays a pivotal role within the broader healthcare sector.
  • This industry undergoes continuous evolution due to ongoing advancements in technology, equipment, diagnostic tools, and medical devices.
  • However, the medical device industry faces distinctive challenges, primarily characterized by stringent regulations across the globe, as discussed in the regulatory section of this report.
  • Emerging market nations also prioritize medical devices as they expand their economies and healthcare expenditures.

New Biosense Webster QDOT MICRO™ Catheter Data Demonstrate Very High-Power, Short-Duration Ablations Improved Quality of Life and Reduced Healthcare Utilization for AFib Patients

Retrieved on: 
Thursday, November 2, 2023
Catheter ablation, Incidence, Johnson & Johnson, Arrhythmia, Heart, RF, Physician, Atrial fibrillation, Elijah Cummings Lower Drug Costs Now Act, Catheter, Journal, Clinical electrophysiology, Quality of life, Caregiver, Recurrence, Electrophysiology, Freedom, Journal of Cardiovascular Electrophysiology, Safety, Cleveland Clinic, Patient, Pharmaceutical industry, Medical device, Nursing, Temperature, MD, Ventricular fibrillation

IRVINE, Calif., Nov. 2, 2023 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced new findings from the Q-FFICIENCY study were published in the Journal of Cardiovascular Electrophysiology demonstrating treatment with the QDOT MICRO™ Catheter significantly improved control of atrial fibrillation (AFib), relief of symptoms and overall quality of life.1

Key Points: 
  • The QDOT MICRO™ Catheter is a next-generation RF ablation catheter that incorporates advanced, high-energy ablation, improved temperature monitoring, optimized irrigation, and higher signal resolution.
  • In QMODE+™ setting, the catheter allows the delivery of very high-power, short-duration ablation – 90 watts for up to four seconds, significantly improving ablation efficiency.2 The QDOT MICRO™ Catheter is fully integrated with the CARTO® 3 System, enabling efficient and consistent lesion creation with a simplified workflow and lower total procedure time.2 Earlier this year, Biosense Webster announced the publication of the Q-FFICIENCY safety and 12-month efficacy data in JACC: Clinical Electrophysiology, which showed that the QDOT MICRO™ Catheter delivered high clinical success with 86% of patients experiencing freedom from symptomatic recurrence while catheter-related primary adverse events remained low at 1.8%.2
    "AFib places a substantial burden on patients' daily lives and healthcare resources, including physician visits, drug costs and side effects, and hospitalizations.
  • At Biosense Webster, we are focused on improving patient outcomes, while offering innovative solutions for physicians treating the growing number of AFib patients today," said Jasmina Brooks, President, Biosense Webster, Inc. "As the Q-FFICIENCY study findings demonstrate, use of the temperature-controlled QDOT MICRO™ Catheter allows physicians to customize treatment for each patient, reduce procedural times and offer significant benefits to patients through improving their quality of life."
  • AFib is the most common type of cardiac arrhythmia affecting an estimated 37.5 million people globally.3 Responsible for more than 450,000 hospitalizations and nearly 5 million physician visits in the U.S. annually, AFib places a heavy burden on patients, their caregivers and healthcare systems.4 Despite these projections, many people are unfamiliar with AFib symptoms, available treatment options and the importance of early treatment to avoid disease progression.5 Catheter ablation is a safe and effective procedure to restore the heart's incorrect electrical signals, which causes an abnormal heart rhythm.6

EQS-News: Bentley Endovascular Group AB brings on-board Keensight Capital, A.P. Moller Holding, and Bonit Capital as new investors

Retrieved on: 
Friday, October 27, 2023
IPO, KOREA, Catheter, Medtech, AFRICA, Health, Moyamoya disease, OR, Dilation, Growth, Marketing, Cardiology, AMERICA, Stent, Delphi, Security (finance), Financial services, Management, Cryptocurrency, Automotive industry, NEW ZEALAND

Bentley Endovascular Group AB brings on-board Keensight Capital,

Key Points: 
  • Bentley Endovascular Group AB brings on-board Keensight Capital,
    Keensight Capital (“Keensight”) invests in Bentley Endovascular Group AB (“Bentley” or “the Group”) alongside A.P.
  • The founders and management retain control and still hold the majority of the capital and the votes in the Swedish holding company Bentley Endovascular Group AB.
  • Headquartered in Stockholm, Sweden, Bentley Endovascular Group AB controls its key subsidiary Bentley InnoMed GmbH and Qmedics AG.
  • Bentley Endovascular Group AB: Stent production at the major site in Hechingen, Germany
    Bentley Endovascular Group AB: Major production site at Hechingen, Germany

Ventric Health Receives FDA 510(k) Clearance for Vivio®

Retrieved on: 
Wednesday, October 25, 2023
FDA, Food, Health, Medicare, Heart failure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Catheter, Transthoracic echocardiogram, SDOH, Transport, Blood, Algorithm, ER, Patient, Diagnosis, Medical device, Pharmaceutical industry, Medical imaging, Subaru Vivio

PASADENA, Calif., Oct. 25, 2023 /PRNewswire/ -- Ventric Health, a healthcare technology company and medical device provider focused on cardiovascular health, today announced that its medical device, the Vivio System™, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). As a result, Vivio empowers clinicians to non-invasively diagnose heart failure within clinical and home health care environments. 

Key Points: 
  • PASADENA, Calif., Oct. 25, 2023 /PRNewswire/ -- Ventric Health, a healthcare technology company and medical device provider focused on cardiovascular health, today announced that its medical device, the Vivio System™, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
  • As a result, Vivio empowers clinicians to non-invasively diagnose heart failure within clinical and home health care environments.
  • Ventric Health co-founder Mory Gharib emphasized, "This is an indispensable clinical insight for clinicians in any care setting.
  • To learn more about Vivio and how Ventric Health is driving the tech-enabled revolution in detecting heart failure, visit the Vivio resource page .

Access Vascular Highlights New Bacterial Adhesion Data at AVA 2023

Retrieved on: 
Tuesday, October 17, 2023
Nursing, Medical Devices, Surgery, Medical Supplies, Hospitals, Cardiology, Practice Management, Biotechnology, Managed Care, Health, PICC, Biomaterial, COVID-19, Hospital, AVA, CLABSI, Platelet, Standard of care, AVI, Bacterial adhesion in aquatic system, Risk, Thrombus, HBM, CMS, Journal, Catheter, Patient, Medical device

Access Vascular, Inc. (AVI) , a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced findings from a new, in vitro study showing a significant reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters (PICC) and midline catheters with AVI’s MIMIX™ hydrophilic biomaterial (HBM).

Key Points: 
  • Access Vascular, Inc. (AVI) , a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced findings from a new, in vitro study showing a significant reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters (PICC) and midline catheters with AVI’s MIMIX™ hydrophilic biomaterial (HBM).
  • The HBM demonstrated a 99.998 percent reduction in bacterial adhesion compared with the standard polyurethane catheter, and a 99.989 percent reduction compared with an augmented polyurethane material.
  • These findings are consistent with previously reported in vitro data on thrombus accumulation, based on platelet count,iv,v with the HBM catheter.
  • “These results highlight the potential for catheters made from MIMIX™ to reduce bacterial adhesion, which often leads to central-line associated bloodstream infections (CLABSI) and has devastating implications for already sick patients,” said James Biggins, CEO of Access Vascular.

T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii

Retrieved on: 
Thursday, October 12, 2023
Bloodstream infections, Food, Bacteria, Intensive care medicine, Acinetobacter baumannii, Risk, Carbapenem, Mortality, World Health Organization, FDA, CE, Escherichia coli, Catheter, ICU, Regulation of tobacco by the U.S. Food and Drug Administration, Pseudomonas aeruginosa, Patient, Infection, Septic shock, Vaccine, Antibiotics

A. baumannii is a cause of bloodstream infections especially in critically ill patients, which can range from a benign transient bacteremia to septic shock.

Key Points: 
  • A. baumannii is a cause of bloodstream infections especially in critically ill patients, which can range from a benign transient bacteremia to septic shock.
  • In a large study of nosocomial bloodstream infections, A. baumannii was the tenth most common pathogen and has a crude ICU mortality rate of 34.0% to 43.4%.
  • “We are excited about the potential to expand the number of pathogens detected by our FDA-cleared T2Bacteria Panel to include the detection of A. baumannii,” stated John Sperzel, Chairman and CEO of T2 Biosystems.
  • Rapid detection of these pathogens is essential to getting infected patients on the appropriate antimicrobial therapy and improving clinical outcomes.

Nanoflex Robotics Secures CHF 2.9M from Swiss Innovation Agency

Retrieved on: 
Monday, October 9, 2023
Physician, Entrepreneurship, Stroke, Intelligence, Innovation Agency (Azerbaijan), Innovation, Robotics, Innovate UK, CHF, Artificial intelligence, Catheter, Patient, Medical device, Pharmaceutical industry

The receipt of the second grant brings Nanoflex Robotics' total non-dilutive grant funding received from Innosuisse this year to CHF 2.9 million.

Key Points: 
  • The receipt of the second grant brings Nanoflex Robotics' total non-dilutive grant funding received from Innosuisse this year to CHF 2.9 million.
  • Innosuisse awarded CHF 400,000 to Nanoflex Robotics, while Brainomix received £400,000 from Innovate UK.
  • In April, Nanoflex Robotics received the inaugural Swiss Accelerator Grant of CHF 2.5 million in non-dilutive funding.
  • Nanoflex Robotics’ first product will be a mobile robotics system that utilizes ultra-flexible guidewires to allow for direct steering control of the tip.